What is pharmacogenomics?
Pharmacogenomics is a new field in a study of pharmacology. For years of prescribing drugs, patients have always had the opportunity to respond well to treatment. One can look at the past medical history for some traces, whether the medicine can cause an undesirable reaction, but there are not many traces in a history. Instead, scientists assume that certain variants in RNA molecules and types of proteins present in the cells are better predictors for assessing the effectiveness of drugs and determining or predicting undesirable reactions. The aim is to adapt drugs to suit each person by assessing the differences in the gene and protein. The theory of pharmacogenomics is that the evaluation of minor deviations in RNA helps scientists, which exactly correspond to the patient's needs and reduce the risk of side effects.
By evaluating specific proteins and disease genes, drugs could be designed to focus on the genetic composition of things such as viruses, bacteria and cancer cells. That couldlead to drugs that are "specific to the disease" and cause less side effects for patients. Some medicines effectively treat the disease, but have very undesirable side effects. If pharmacogenomics find a way to attack the disease without attacking the patient's body, it can dramatically improve medical treatment.
vaccines can be more effective if they focus on people with different types of proteins and genes. Those in pharmacogenomics also assume that drug research would be more effective and that drug testing would be less extensive because genetic profiles would determine which Indiviiduals would benefit from newly developed drugs. This could lead to lower research and testing costs.
Most pharmacogenomics depend on the fact that people agree to test their genetic code, and not every individual supports it. For automated health care systems some people concernThe genetic code that shows a greater risk of certain types of diseases could get into the hands of employers or health insurance companies. It is said that those who are susceptible to certain diseases can have a harder time to get work or health insurance. In order to be successful in pharmacogenomics, people must be willing to test and evaluate their genetic code, and not everyone will follow it.
Some other problems with pharmacogenomics are currently huge varieties of protein sequences, called one nucleotide polymorphisms (SNP). One variant can change the individual's pharmaceutical needs and can take a long time to find one variant. At this time, medical scientists do not necessarily know which genes respond to or how they respond to them.
Another problem of pharmacogenomic meetings is the current idea of mass production of individual drugs by pharmaceutical companies. This thinking of "one -size medication throws all" would have to be pharmaceutical withPoly refused in favor of creating much smaller batches of drugs or vaccines, precisely adapted to certain genetic codes. Furthermore, there would be a significant learning curve for prescribing drugs based on pharmacogenomics. They would have to learn how to analyze the variations of the gene of each patient to know what to prescribe and at what dosage.
The field of pharmacogenomics still has a big promise. For those who cannot take certain drugs for adverse reactions, there is a hope that drugs could sometimes deal with the specific health needs of each individual. However, it is necessary to make much more research into the pharmacogenomics into practice in the range.